Amneal director gifts 20,445 shares to trust

A director of Amneal Pharmaceuticals transferred 20,445 AMRX shares as a gift to a trust, shifting part of his holdings from direct to indirect ownership.

Available on EDGAR 09/21/2026 - 04:36 PM EDT Accepted by SEC EDGAR 09/21/2026 - 04:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. (AMRX) director J. Kevin Buchi reported a bona fide gift of 20,445 shares of Class A Common Stock on September 17, 2026. The shares were transferred for no consideration to a trust for which he serves as trustee. After the transfer, he held 75,077 shares directly and 113,944 shares indirectly through the trust. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

20,445 shares gifted

Gift 1 txn

Insider BUCHI J KEVIN

Role Director

Type	Security	Shares	Price	Value
Gift	Class A Common Stock F1	20,445	$0.00	$0.00
Holding	Class A Common Stock F1	--	--	--

Holdings After Transaction: Class A Common Stock — 75,077 shares (Direct); Class A Common Stock — 113,944 shares (Indirect, By Trust)

Footnotes (1)

1. F1. On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust.

Key Figures

Gifted shares: 20,445 shares Per-share price on gift: $0.00 per share Direct holdings after transaction: 75,077 shares +2 more

5 metrics

Gifted shares 20,445 shares Bona fide gift of Class A Common Stock on September 17, 2026

Per-share price on gift $0.00 per share Gift transfer of 20,445 shares for no consideration

Direct holdings after transaction 75,077 shares Class A Common Stock held directly after September 17, 2026 gift

Indirect holdings after transaction 113,944 shares Class A Common Stock held indirectly "By Trust" after the transfer

Gift transactions reported 1 transaction Single bona fide gift of Class A Common Stock in this Form 4

Key Terms

bona fide gift, Class A Common Stock, indirect ownership, trustee

4 terms

bona fide gift financial

"transaction code description is "Bona fide gift" for the transfer"

A bona fide gift is a genuine, voluntary transfer of money, property, or benefits from one party to another made without expectation of repayment, services, or hidden conditions. Investors care because such gifts can affect company disclosures, related‑party transaction rules, tax treatment, and perceived conflicts of interest; think of it like someone giving you a present with no strings attached — but on a corporate scale, auditors and regulators need to verify it really is unconditional.

Class A Common Stock financial

"security title is listed as "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

indirect ownership financial

"ownership type marked indirect with nature "By Trust""

trustee financial

"the reporting person is trustee of the trust"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AMRX director J. Kevin Buchi report?

He reported a bona fide gift of 20,445 shares of Amneal Pharmaceuticals Class A Common Stock on September 17, 2026, transferring them to a trust for no consideration while serving as trustee of that trust.

How many AMRX shares did the director transfer and at what price?

He transferred 20,445 shares of Class A Common Stock as a gift for no consideration. The Form 4 shows a per-share price of $0.00, consistent with a non-cash gift transaction.

What are J. Kevin Buchi’s AMRX holdings after the reported gift?

Following the gift, he held 75,077 shares of Amneal Class A Common Stock directly and 113,944 shares indirectly, described as held "By Trust" where he is the trustee.

Was the AMRX insider gift made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox indicates no Rule 10b5-1 plan is reported in connection with these transactions.

How is the trust ownership of AMRX shares described in the Form 4?

The Form 4 states that 20,445 shares were transferred to a trust for no consideration and identifies the reporting person as trustee of the trust, with 113,944 shares shown as indirectly owned "By Trust."

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUCHI J KEVIN

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/17/2026		G(1)	V	20,445	D	$0	75,077	D(1)
Class A Common Stock								113,944	I	By Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)